ArticleAJNR. American journal of neuroradiology2012
Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
Article in AJNR. American journal of neuroradiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 7 syntheses or guidelines pooled it, 295 citations in OpenAlex.
- Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review.Neuroradiology · 2021Pooled it
- Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.European radiology · 2019Pooled it
- Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review.The British journal of radiology · 2018Pooled it
- 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.Neuro-oncology · 2018Pooled it
- Clinically Relevant Imaging Features forAJNR. American journal of neuroradiology · 2018Pooled it
- Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.Molecular neurobiology · 2016Pooled it
- The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.Neurochemical research · 2014Pooled it
- Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Mechanical compression induces neuronal apoptosis, reduces synaptic activity, and promotes glial neuroinflammation in mice and humans.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study.BMC medical imaging · 2025Article
- Solid Stress Estimations via Intraoperative 3D Navigation in Patients with Brain Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Article
- Structured reporting of gliomas based on VASARI criteria to improve report content and consistency.BMC medical imaging · 2025Article
- Unraveling the heterogeneity of WHO grade 4 gliomas: insights from clinical, imaging, and molecular characterization.Discover oncology · 2025Article
- Virtual Biopsy for the Prediction of MGMT Promoter Methylation in Gliomas: A Comprehensive Review of Radiomics and Deep Learning Approaches Applied to MRI.Diagnostics (Basel, Switzerland) · 2025Review
- A multitask framework based on CA-EfficientNetV2 for the prediction of glioma molecular biomarkers.Frontiers in neurology · 2025Article
- Explainable, modality-adaptive radiomics for MGMT methylation prediction in high-grade glioma: a decision-curve analysis study.Frontiers in oncology · 2025Article
- Noninvasive MGMT-promotor methylation prediction in high grade gliomas using conventional MRI and deep learning-based segmentations.Frontiers in neuroscience · 2025Article
- Immune intrinsic escape signature stratifies prognosis, characterizes the tumor immune microenvironment, and identifies tumorigenic PPP1R8 in glioblastoma multiforme patients.Frontiers in immunology · 2025Article
- Auxiliary diagnosis of primary bone tumors based on Machine learning model.Journal of bone oncology · 2024Article
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeBoth IDH1 mutation and MGMT promoter methylation are associated with longer survival. We investigated the ability of imaging correlates to serve as noninvasive biomarkers for these molecularly defined GBM subtypes. MATERIALS AND
methodsMR imaging from 202 patients with GBM was retrospectively assessed for nonenhancing tumor and edema among other imaging features. IDH1 mutational and MGMT promoter methylation status were determined by DNA sequencing and methylation-specific PCR, respectively. Overall survival was determined by using a multivariate Cox model and the Kaplan-Meier method with a log rank test. A logistic regression model followed by ROC analysis was used to classify the IDH1 mutation and methylation status by using imaging features.
resultsMGMT promoter methylation and IDH1 mutation were associated with longer median survival. Edema levels stratified survival for methylated but not unmethylated tumors. Median survival for methylated tumors with little/no edema was 2476 days (95% CI, 795), compared with 586 days (95% CI, 507-654) for unmethylated tumors or tumors with edema. All IDH1 mutant tumors were nCET positive, and most (11/14, 79%) were located in the frontal lobe. Imaging features including larger tumor size and nCET could be used to determine IDH1 mutational status with 97.5% accuracy, but poorly predicted MGMT promoter methylation.
conclusionsImaging features are potentially predictive of IDH1 mutational status but were poorly correlated with MGMT promoter methylation. Edema stratifies survival in MGMT promoter methylated but not in unmethylated tumors; patients with methylated tumors with little or no edema have particularly long survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.